Recruitment sites and Imaging hubs

WB-MRI protocol minimum dataset
Scanning maybe performed at either 1.5T or 3T. Whole body is head to mid-thigh 1. Whole-body diffusion weighted imaging: Axial: STIR-EPI (or other fat sat technique) diffusion weighted imaging. Fixed slice thickness of 5mm to 7mm (to match T2 and T1 weighted axials as below) two b-values (b50 and b900). A minimum acquisition matrix of 128 x 128 (or an interpolated equivalent) (rectangular FOV should be used if available and appropriate for the patient), as a reference a minimum SNR of 6 on b50 images (for liver) should be maintained by increasing the number of averages. All imaging should be performed in gentle respiration (recommended as 4 stations of 50 slices beginning from the vertex to mid thighs). Diffusion imaging through the brain is optional. 2. Whole-body T2 weighted imaging: Axial: Axial T2 weighted (without fat-suppression) imaging, maximum 5 to 7 mm slice thickness. Where possible, respiratory and ECG triggering should be used for the chest, respiratory triggering alone for the upper abdomen. Pre-contrast T1 weighted imaging: DIXON Technique to be applied if available. a.
Axial: Whole-body T1 GRE (e.g. Flash 2D) non-contrast enhanced non fat sat. Image resolution and slice thickness should be ideally matched to T2 weighted imaging. OR b.
Coronal: T1 fat saturated volume interpolated gradient echo imaging (e.g. 3D) pre contrast.
Post-contrast T1 weighted imaging (if gadolinium not contraindicated or refused):
Minimum data set Axial liver (60-70 sec) Axial lung (equilibrium phase) SFOV axial head Optional Coronal (organ specific or whole body) a.
Axial: post contrast e.g. T1 fat saturated volume interpolated gradient echo imaging (3D) breath hold of the liver (60-70 seconds delay) and lungs. Multiple breath-holds employed to provide full volume coverage if required. A minimum of a 256x256 (rectangular FOV acquisition if possible and appropriate for the patient) acquisition matrix should be employed. 5-7 mm slice thickness. b.
Coronal: post contrast whole body; e.g. T1 fat saturated volume interpolated gradient echo imaging (3D) and post contrast. Slice thickness 5mm. Breath Hold. c.
Axial: fat saturated T1 weighted imaging of the brain (SFOV). An acquisition matrix of 256 x 256 should be employed
Summary of information recorded by the MDT and categories of treatment decisions
• Stage and treatment decision based on standard investigations (and the number, timing, nature and findings of these investigations).
• Stage and theoretical treatment decision based on WB-MRI staging pathway (and the number, timing, nature and findings of additional tests generated, if any).
• Final treatment decision incorporating all available tests.
Categories of treatment decisions
• Surgical removal of primary alone • Surgery for primary followed by planned adjuvant chemotherapy • Surgery for primary followed by planned chemotherapy followed by surgical removal of metastasis • Surgical removal of primary and metastatic site(s) alone • Surgery for primary and metastatic site(s) followed by planned adjuvant chemotherapy • Neo-adjuvant chemo (radio) therapy alone • Neo-adjuvant chemo (radio) therapy alone followed by planned surgical removal of primary • Neo-adjuvant chemo (radio) therapy alone followed by planned surgical removal of primary and metastatic site(s)
Criteria for diagnosis of metastatic disease by the consensus reference panel
• For patients in whom the primary tumour was completely removed within 3 months of diagnosis, all new metastatic sites identified over the follow up period were assumed to have been present at diagnosis • If the primary tumour was left in situ for more than 3 months of diagnosis (or there was incomplete removal), new metastatic sites were assumed to have been present at diagnosis if they were identified within 6 months of diagnosis If new metastatic sites were diagnosed beyond 6 months of diagnosis, and there was no evidence of their presence on retrospective review of all staging investigations, they were assumed to be new disease and not present at diagnosis • If patients with tumours left in situ did not undergo any imaging capable of detecting metastatic disease within 6 months of diagnosis of the primary and new metastatic sites were apparent beyond 6 months but not visible in retrospect on any trial imaging, the consensus panel decided if the disease was likely present at diagnosis, based on its location, size and imaging characteristics.
• If a patient died before the 12 months' follow-up, the panel reviewed all available imaging, histopathology and clinical course prior to death and in consensus decided if a confident diagnosis of the presence or absence of metastatic disease could be made (for example the presence of imaging characteristics compatible with metastasis and no alternative explanation, or if lesions with characteristics compatible with metastasis that either grew or shrunk (on therapy). If this judgement could not be made with confidence (for example if the patient had equivocal lesions on staging investigations and no further follow up), patients were not be excluded but multiple imputation used to account for missing data
Grouping of treatment decision for analysis
Treatment decision category Treatment decisions included
Surgery for the primary but no chemotherapy
• Surgical removal of primary alone Surgery for the primary & chemotherapy (and/or radiotherapy)
• Surgery for primary followed by planned Adjuvant chemotherapy • Neo-adjuvant chemo (radio) therapy alone followed by anticipated surgical removal of primary Chemotherapy (and/or radiotherapy) without surgery
• Neo-adjuvant chemo (radio) therapy alone • Palliative care Surgical metastectomy with or without chemotherapy
• Surgery for primary followed by planned chemotherapy followed by surgical removal of mets • Surgical removal of primary and metastatic site(s) alone • Surgery for primary and metastatic site (s) followed by anticipated Adjuvant chemotherapy • Neo-adjuvant chemo (radio) therapy alone followed by anticipated surgical removal of primary AND metastatic site(s)
Justification for economic analysis
As per the trial protocol, a full economic evaluation was not performed because of the observed concordance between WB-MRI and conventional staging tests in informing treatment decisions. The care pathway may be divided into two stages: the treatment decision pathway and the subsequent disease pathway. The former includes the time from initial diagnosis to treatment decision by the MDT; the latter includes the time period following the treatment decision. If there is no difference in treatment decisions made with the two different staging methods, the only difference in costs assigned to the two staging methods is the differential costs of the two sets of staging tests (i.e. standard staging vs. WB-MRI pathway, including additional tests requested), and there will be no difference in treatment pathways or outcomes on the basis of the experimental staging tests used and the resulting costs. As specified in the trial protocol, concordance between conventional staging and WB-MRI was defined as the situation in which >90% of treatment decisions were the same using both imaging methods, or <10% treatment decision were different. Discordance was defined as the case in which >10% treatment decisions were different, or <90% were the same. In the protocol we specified that in the case of concordance, the economic analysis would focus on the cost of the treatment decision pathways only, because the disease pathways will be no different. In this case the cost-effectiveness of WB-MRI versus conventional staging algorithms depends only on the incremental cost (positive or negative) of WB-MRI versus conventional staging algorithms in the treatment decision pathway. Conversely, if there is discordance between the treatment decisions, suggesting that patients would have received different treatment depending on which of the two experimental staging methods was used, then the economic analysis ought to include both the treatment decision pathways and the subsequent disease pathways because both of these will vary between WB-MRI and conventional staging algorithms. In this case the costeffectiveness of WB-MRI depends on the incremental cost of the WB-MRI versus conventional staging algorithms in the treatment decision pathway plus the incremental costs and health benefits of the disease pathway.
The agreement with the MDT final treatment decision was 96% and 95% for WB-MRI and standard pathways respectively, clearly indicating there was concordance between conventional staging and WB-MRI. On this basis, as specified in our trial protocol, the economic analysis focused on a comparison of the costs of the treatment decision pathways only, which is the analysis included in the manuscript. 
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